Author:
Mahadeo Kris M,Bajwa Rajinder,Abdel-Azim Hisham,Lehmann Leslie E,Duncan Christine,Zantek Nicole,Vittorio Jennifer,Angelo Joseph,McArthur Jennifer,Schadler Keri,Chan Sherwin,Tewari Priti,Khazal Sajad,Auletta Jeffery J,Choi Sung Won,Shoberu Basirat,Kalwak Krzysztof,Harden Avis,Kebriaei Partow,Abe Jun-ichi,Li Shulin,Moffet Jerelyn Roberson,Abraham Susan,Tambaro Francesco Paolo,Kleinschmidt Katharina,Richardson Paul G,Corbacioglu Selim
Reference72 articles.
1. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial;Corbacioglu;Lancet,2012
2. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients;Barker;Bone Marrow Transplant,2003
3. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation;Cesaro;Haematologica,2005
4. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide;Corbacioglu;Bone Marrow Transplant,2006
5. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population;Richardson;Blood,1998
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献